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Abstract
Interleukin 13 (IL-13) is immunoregulatory in many diseases, including cancer. The protective or suppressive role of
CD1-restricted natural killer T cells (NKT cells) in tumor immunosurveillance and immunity is well documented.
Interleukin 12 (IL-12) can activate type I NKT cells to produce interferon-gamma (IFN-γ), whereas type II NKT cells
may produce IL-13. The high-affinity chain of IL-13Rα2 may act as negative inhibitor, suppressing the action of
IL-13 and helping to maintain tumor immunosurveillance. We constructed an mIL-13Rα2-Fc chimera in a eukaryotic
expression vector and confirmed the identity of the recombinant protein by immunoblot analysis and binding to
IL-13 in chemiluminescent ELISA. Such DNA vaccine was tested against syngeneic B16F10-Nex2 murine mela-
noma. In vivo experiments showed a protective effect mediated by high production of IFN-γ and down-regulation
of anti-inflammatory interleukins mainly by NKT 1.1+ T cells. Biochemoterapy in vivo with plasmid encoding mIL-
13Rα2-Fc in association with plasmid encoding IL-12 and the 7A cyclopalladated drug led to a significant reduction
in the tumor evolution with 30% tumor-free mice. We conclude that IL-12 gene therapy, followed by continuous
administration of IL-13Rα2-Fc gene along with 7A-drug has antitumor activity involving the high production of
proinflammatory cytokines and low immune suppression, specifically by NK1.1+T cells producing IL-13 and IL-10.
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Introduction
The challenge in the development of anticancer vaccines has been
to elicit cellular immune responses that may effectively control tumor
growth despite the negative regulatory mechanisms that are simulta-
neously induced. To increase the antitumor response, diverse modal-
ities of gene therapy have been used, such as administration of genes
encoding proinflammatory cytokines or inhibitors of immune sup-
pressor components. Cells inducing immunosuppressive responses
include CD4+CD25+ T-regulatory (T-reg) cells, conventional TH2
cells, CD1d-restricted natural killer T cells (NKT cells), myeloid sup-
pressor cells, and M2 macrophages [1–5].
CD1d-restricted NKT cells have a dual role in tumor immunity,
depending on different cell subsets [6]. They have been implicated
in the down-regulation of immunosurveillance in tumor models
[3,4,7] and in the promotion of antitumor immunity [8–10]. These
opposing activities are explained by the recruitment of selected NKT
subpopulations producing different cytokine profiles, depending on
the stimulus or microenvironment. Dendritic cells (DCs) pulsed with
α-galactosylceramide (α-Gal-Cer) inhibited metastasis in experimental
melanoma [11]. The Vα14-Jα18 NKT cells were the first to be ac-
tivated after administration of IL-12, displaying in vitro cytotoxicity in
B16 tumor cells and in vivo protection against the subcutaneous
growth and pulmonary colonization by B16 murine melanoma [12].
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In contrast, Ahlers et al. [13] found that the suppression of a
cytotoxic T lymphocytes-inducing vaccine apparently was due at
least in part to NKT cells, because they were able to enhance vaccine
efficacy by blockade of IL-13 or by using CD1-deficient mice that
lack NKT cells. Terabe et al. [14] showed that, in the absence of both
type I NKT cells and T-reg cells, type II (non-Vα14Jα18+) NKT
cells were responsible for suppression of immunosurveillance. There-
fore, NKT cells can regulate positively or negatively the immune re-
sponse, and a strategy that would involve stimulation of NKT type I
subpopulation (e.g., by administering IL-12) and suppression or con-
trol of NKT type II cells might render a more efficient antitumor
immune response.
NKT type II cells regulate negatively the immune response prob-
ably through the production of IL-13. First described in 1993 [15],
IL-13 is secreted preferentially by activated TH2 lymphocytes and
NKT cells, but macrophages, DCs, NK cells, mast cells, and baso-
phils can also produce it. This interleukin inhibits inflammatory
cytokine and chemokine production, up-regulates MHC class II
expression and CD23 on monocytes [15,16], increases the expression
of VCAM-1 on endothelial cells [17], and promotes B-cell prolif-
eration and IgE class switching [18,19]. It plays crucial roles in the
pathophysiology of allergic asthma, helminthiasis, autoimmune dis-
orders, and chronic diseases [20]. IL-13 signaling requires binding to
the IL-13Rα1 receptor, which then forms heterodimers with the
IL-4 receptor (IL-4Rα) [21–23]. IL-13, however, shows higher af-
finity binding to the α2 chain of the IL-13 receptor (IL-13Rα2),
which may function as a decoy receptor and is important to down-
regulate a TH2-mediated immune response [24]. This chain is unable
of signaling because it has a short cytoplasmic tail and does not ac-
tivate the STAT6 pathway [25]. However, Fichtner-Feigl et al. [26]
found that IL-13 binding to IL-13Rα2 may activate AP-1 transcrip-
tional factor to induce secretion of transforming growth factor beta
(TGF-β).
The role of IL-13 on tumor immunity seems to be complex and
may depend on both the tumor type and the genetic background of
the host. Previous studies have shown that IL-13 enhanced antitumor
responses in some model systems [27] or did not affect tumor growth
[28,29]. Conversely, mIL-13Rα2-Fc prevented IL-13–mediated sup-
pression of tumor immunosurveillance [3,14]. In a 15-12RM fibro-
sarcoma model of tumor recurrence, the authors showed that CD8+
CTL-mediated tumor elimination was suppressed by IL-13 produced
by CD1d-restricted T cells and activated IL-4Rα–STAT6 signaling
pathway. IL-4αR knockout (KO) and STAT6 KO mice but not
IL-4 KO mice were resistant to tumor recurrence. When these IL-4
KO mice were treated with soluble inhibitor of IL-13, they became
resistant to tumor recurrence indicating that IL-13 was responsible
for the suppression of tumor immunosurveillance in this model. More-
over, CD1d-KO mice were also resistant to tumor growth because
they lack NKT cells hence did not produce IL-13. In a metastasis
model of colon carcinoma, the same mechanism was observed where
treatment with soluble protein IL-13Rα2-Fc diminished the number
of metastasis [7]. An effector mechanism in this suppressive path-
way was proposed by Terabe et al. [4], who showed that CD11b+
Gr-1+ myeloid cells produced TGF-β by a mechanism dependent on
the presence in vivo of both IL-13 and CD1d-restricted T cells. Because
T cells do not respond to IL-13 [16], other cells are stimulated to pro-
duce TGF-β that can be the cytokine responsible for the inhibition
of CTL activity. Now, this hypothesis can be examined by studying
IL-13Rα2 chain function inmacrophages responding to IL-13 [26,30].
Therapy with soluble mIL-13Rα2-Fc leads to antitumor response
in models where type II NKT cells inhibit natural tumor immuno-
surveillance by a mechanism involving IL-13, whereas IL-12 stimu-
lates several antitumor pathways, including type I NKT activation.
Here, we associated gene therapy with chemotherapy by using a
cyclopalladated drug (7A) that has been shown to be protective in
mice challenged subcutaneously with B16F10-NEX2 melanoma cells
[31]. The combination of gene therapy and chemotherapy conferred
increased protection against melanoma with 30% mice free of tumor
at the end of experiment.
Materials and Methods
Cell Lines and Reagents
B16F10-Nex2 is a subline from B16F10 murine melanoma [32],
isolated at the Experimental Oncology Unit (UNONEX). It is char-
acterized by low immunogenicity and moderate virulence. The mela-
noma cells were maintained in culture in RPMI 1640 medium
pH 7.2, supplemented with 10% heat-inactivated fetal calf serum,
10 mM HEPES (N -2-hydroxyethylpiperazine-N -2-ethanesulphonic
acid), 24 mM NaHCO3, all from GIBCO (Minneapolis, MN), and
40 mg/ml gentamycin sulfate (Hipolabor Farmacêutica, Sabará, MG,
Brazil). Monoclonal antibodies (mAbs) conjugated with phycoery-
thrin (PE) against mouse CD3, CD4, and CD8, mAbs conjugated
with flourescein isothiocyanate (FITC) against mouse NK1.1 and
F4/80, and mAbs biotinylated against cytokines were all purchased
from PharMingen (San Diego, CA).
Mice
Inbred male 6- to 8-week-old C57BL/6 mice were purchased
from Centro de Desenvolvimento de Modelos Experimentais at Fed-
eral University of São Paulo (UNIFESP). All animal experiments
were approved by the Animal Experimental Ethics Committee of
UNIFESP, protocol number 1340/2003. In all experiments, 10 mice
were used per group.
Construction of the mIL-13Rα2-Fc DNA Vaccine
To construct the mIL-13Rα2-Fc (murine IL-13 receptor alpha-2/
IgG2a Fc fusion protein) chimera, the sequence corresponding to
the extracellular domain of the receptor (amino acids 1-332) was ob-
tained from macrophage total RNA, whereas those from Fc regions
(CH2-CH3) were amplified from hybridoma 17C [33], both using
reverse transcription–polymerase chain reaction (RT-PCR). RNA ex-
tractions from mouse peritoneal macrophages pretreated with IL-13
and from hybridoma 17C were carried out using Trizol reagent
(Invitrogen Brasil, São Paulo, Brazil), following the manufacturer’s in-
structions with minor modifications. Reverse transcription–polymerase
chain reaction was performed using “Thermo Script RT-PCR Sys-
tem” (Invitrogen) and oligo dT, according to the manufacturer’s instruc-
tions. DNA was eliminated after treatment with DNase I (Rnase-free;
Amersham GE Healthcare, Piscataway, NJ), and controls without
reverse transcription were included in all reactions. The PCR mixture
consisted of 1/10 of the RT reaction, Taq buffer (20 mM Tris-HCl
pH8.4, 50mMKCl), 200 μMdeoxynucleoside triphosphates (dNTP),
1.5mMMgCl2, 2.5 UTaqDNApolymerase (Invitrogen), and 1 μMof
each primer. The oligonucleotide primers used to amplify mIL-13Rα2
and Fc region were as follows: 5′ -d GTCGAC ATGGCT TTTGTG
CATATC AGATGC- 3′ (forward, P1); 5′ -d TCC GGA GCC CTT
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TGA GTC TGG CCC TGT GTA- 3′ (reverse, P2) and 5′ -d GGC
TCC GGAM GCA CCT AAC CTC TTG GGT G- 3′ (forward,
P3); 5′ -d TCTAGATCATTTACC CGG AGTCCGGGA- 3′ (re-
verse, P4). The mIL-13Rα2 and Fc coding sequences were amplified
after 35 cycles at 94°C for 1 minute, 59°C (or 60°C for Fc) for 2 min-
utes, and 72°C for 1minute. Each fragments was cloned into a pGEM-
Teasy vector (Promega, Madison, WI), the inserts were automatically
sequenced, and the sequences compared with those available in the
GenBank (IL-13Rα2, gi = 6680404; CH2-CH3 IgG2a, gi =
51767065 and gi = 406252). Nucleotide sequencing was carried
out in the facilities of the Center of Human Genome at São Paulo
University (USP). To generate the final construct (1656 bp) encod-
ing IL-13Rα2 fused in frame with the Fc region through the spacer
Gly-Ser-Gly, we followed a modified PCR overlap technique [34]
using both plasmids as template (10 ng in 25 μl of reaction mixture).
The first round of PCR (35 cycles at 95°C for 30 seconds, 55°C for
30 seconds, and 72°C for 2 minutes) was run in the presence of
0.4 μMof each internal primer (P2, P3), 1 μMof each external primer
(P1, P4), Taq buffer, 1.5 mM MgCl2, 200 μM of each dNTP, and
2.5 U of platinum Taq polymerase (Invitrogen). Reamplification of
the product, used as template at 1:100, took only external primers,
at an annealing temperature of 58°C. Polymerase chain reaction prod-
ucts were purified using “Bioclean for Purification of DNA Bands”
(Biotools, Brazil) and cloned into a pGEM-T vector. The sequence
of the final construct was confirmed by automatically sequencing
the insert in both directions using sense T7 and antisense SP6 vector
primers. The insert was then subcloned into a Sal I restriction site
of a VR1012 vector (Vical Co., San Diego, CA), which was used to
transform DH5α bacteria by heat shock. Plasmids from a selected
clone were purified in CsCl gradient with ethidium bromide after
ultracentrifugation at 500,000g for 16 hours (VTi 90 rotor; Beckman,
Fullerton, CA), followed by washing with saturated butanol (to re-
move bromide). Plasmids were precipitated with ethanol 100% for
3 days, washed twice with ethanol 70%, and then resuspended in
sterile phosphate-buffered saline (PBS).
Production and Analysis of the Recombinant
Protein IL-13Rα2-Fc
B16F10-Nex2 tumor cells were transiently transfected with 5 μg
of the expression plasmid with lipofectin (Invitrogen). Culture su-
pernatants that contained secreted mIL-13Rα2-Fc were filtered
through Millipore Millidisk (0.22 μm) and purified through protein
G Sepharose affinity chromatography (Pharmacia, Uppsala, Sweden).
The solid phase was equilibrated with PBS pH 7.4, washed with
PBS, and eluted with 0.1 M glycine, pH 2.8. The eluate was neu-
tralized by 1:5 volume of Tris-HCl 1 M, pH 9.0. The final product
was examined by reducing SDS-PAGE stained with silver nitrate
and its identity confirmed by immunoblot analysis. Briefly, the sam-
ple was reduced with DTT, separated in 8% SDS-PAGE, and then
transferred onto a nitrocellulose membrane (0.2 μm; Amersham
Bioscience, England) by electroblot analysis. The blot was blocked
with PBS containing 5% dry skim milk and then incubated over-
night at 4°C with biotinylated polyclonal goat antibody to murine
IL-13Rα2 (0.2 μg/ml; R&D Systems, São Paulo, Brazil) diluted in
PBS–1% BSA (bovine serum albumin). After three washes with
0.05% Tween 20 in PBS (PBST) and once with PBS, horseradish
peroxidase–conjugated streptavidin (1:1000; Jackson Immuno-
Research Laboratories, West Grove, PA) was added (1 hour at 37°C).
The blot was developed with 5 mg of DAB (Sigma, São Paulo, Brazil)
and 100 μl of H2O2 in PBS and blocked with distilled water. The
biologic activity (high and specific interaction with IL-13) was assessed
in a chemiluminescent enzyme-linked immunosorbent assay (ELISA).
Briefly, white immulon-2 plates (Nunc, Roskilde, Denmark) were coated
with recombinant murine IL-13 (2 μg/ml; Peprotech, Ribeirão, Brazil)
in PBS overnight. Plates were washed with PBST and blocked with
PBS– 1% BSA (3 hours at 37°C). Purified supernatant from trans-
fected cells diluted in PBS–1%BSAwas added and incubated for 3 hours
at 37°C. Biotinylated goat antimouse IL-13Rα2 (1 μg/ml; R&D Sys-
tems) was added and incubated overnight at 4°C. Peroxidase-labeled
streptavidin (1:1000; 1 hour at 37°C) was used to detect biotinylated
Ab. Finally, 1:50 ECL (Enhanced Chemiluminescent detection kit;
Amersham Pharmacia Biotech) was added, diluted in 0.5 M carbonate-
bicarbonate buffer pH 9.6. Readings (relative luminescent units) were re-
corded in a luminometer (Cambridge Technology, Auburn, CA). The
concentration of mIL-13Rα2-Fc in the sample was determined from a
serial-fold diluted standard mIL-13Rα2-hIgG1 (R&D Systems). Con-
trols with empty vector were used in all experiments.
IL-12 Plasmid
The expression vector encoding IL-12 was provided by Alexander
Rakhmilevich [35] from the University of Wisconsin and tested for
in vitro activity before gene therapy. The plasmid (pWRG3169) con-
tains sequences encoding the p35 and p40 subunits of murine IL-12,
localized in opposite direction and each driven by its own cyto-
megalovirus (CMV) i/e promoter/enhancer, simian virus 40 sd/sa
intron sequence, bovine growth hormone polyadenylation sequence,
and ampicillin-resistant gene. A control vector containing luciferase
cDNA under the CMV promoter was constructed as described by
Cheng et al. [36].
To confirm the production of IL-12, this plasmid was used to
transfect B16F10-Nex2 tumor cells as described above, followed
by ELISA of the supernatant. The biologic activity of the recombi-
nant IL-12 was tested by production of nitric oxide (NO) in a mac-
rophage activation assay. Nitric oxide was quantified as nitrite by
Griess reagent.
Cyclopalladated Drug
The cyclopalladated drug 7A was synthesized from N ,N -dimethyl-
1-phenethylamine, complexed to 1,2 ethanebis(diphenylphosphine)
ligand, and was active in vitro and in vivo against B16F10-Nex2 mu-
rine melanoma cells as previously described [31].
In Vivo Experiments
C57Bl/6 male mice were injected subcutaneously in the right
flank with 5 × 104 B16F10-Nex2 viable tumor cells, and on day
2, the animals were vaccinated with pIL-12 (100 μg per animal)
or with the empty plasmid, intradermally at the tail base. The treat-
ment with 10 μM of the 7A drug started 4 days later, three times
a week by intraperitoneal route, until the tumor volume reached
2 cm3. On day 5 and subsequently at 5-day intervals, the animals
received the pIL-13R vaccine (VR1012 vector + mIL-13Rα2-Fc)
or the respective empty plasmid (100 μg/animal), i.d. at the tail base,
until day 30. The therapeutic efficacy was evaluated by tumor growth
and survival index. The tumor volume was measured every 3 days
using a caliper according to the formula: V = 0.52 × D1
2 × D3, where
D1 and D3 are the short and long diameters, respectively. All experi-
ments included 10 mice per group, and the animals with maximum
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3 cm3 tumor size were killed. Survivals of mice were scored and sta-
tistically compared (Kaplan-Meier log rank test).
Flow Cytometry
A possible correlation between the immune protection of treated
animals and the leukocyte populations producing cytokines (IFN-γ,
IL-12, IL-10, IL-6, IL-4, IL-13, IL-2, TNF-α, and TGF-β) was as-
sessed by using fluorescence-activated cell sorting (FACS). All mice
(control or vaccinated) were evaluated individually, and when the
tumor diameter reached a maximum of 3 cm3, splenocytes were col-
lected. T CD4+, T CD8+, F4/80+, and NK1.1+T cells (CD3+NK1.1+,
CD4+NK1.1+ or CD8+NK1.1+) and their intracellular cytokine pro-
duction were immediately analyzed ex vivo without restimulation.
Briefly, splenocytes were harvested and erythrocytes were lysed by
osmotic shock (0.1 M NH4Cl, pH 7.2). Cells were incubated with
PBS–1%BSA for 10minutes on ice, washed twice in 1% PBS, and the
Fc receptors were blocked with inactivated mouse serum for 1 hour on
ice. Monoclonal antibodies anti–CD3, CD4, CD8, F4/80 andNK1.1
were added, and the samples were incubated for 1 hour on ice in the
dark. Cells were then washed and permeabilized with saponin buffer
(0.5% saponin, 1% paraformaldehyde in PBS). After incubation with
inactivated mouse serum for 1 hour on ice, the cells were incubated
with biotinylated antibodies against cytokines, followed by incubation
with FITC-conjugated streptavidin, PE-conjugated streptavidin or al-
lophycocyanin (APC)–conjugated streptavidin (all fromPharMingen).
Controls with these reagents alone were run in all assays. Cells were
then fixed with 2% paraformaldehyde in PBS (wt/vol) and surface
and intracellular fluorescence wasmeasured using a FACSCalibur flow
cytometer (BD Biosciences, São Paulo, Brazil). Data were collected for
10,000 viable cells and analyzed using CellQuestPro software (Becton
Dickinson, San Jose, CA).
Statistical Analysis
Significant differences were assessed using Student’s t test. All ex-
periments were conducted two or more times. Reproducible results
were obtained, and representative data are shown. The survival plots
were analyzed by Kaplan-Meier log rank test. In both tests, the dif-
ferences were considered statistically significant when P < .05. Cyto-
kine production relating treated and untreated animals was evaluated
by ANOVA, nonparametric Dunn test.
Results
Construction of the mIL-13Rα2-Fc DNA Vaccine
The coding sequence to the extracellular domain of the IL-13 re-
ceptor was cloned from total RNA of macrophages pretreated with
IL-13 for 48 hours [37] and RT-PCR generated a fragment of 1002 bp,
whereas the coding sequences to the Fc regions (CH2-CH3) were
cloned from total RNA of hybridoma 17C [33]. Our PCR conditions
could not detect the expression of the IL-13Rα2 chain in nonstimu-
lated macrophages. A modified PCR overlap technique was used to
generate the final construct, IL-13Rα2 fused in frame with Fc region
and with a Gly-Ser-Gly spacer, as shown in Figure 1. The final con-
struct was confirmed by sequencing, subcloned into the Sal I restric-
tion site of a VR1012 expression vector, and was called pIL-13R.
BamH I restriction showed the correct direction of the insert (not
shown). Plasmids were purified through CsCl gradient with ethidium
bromide and used for in vitro transfection and in vivo experiments.
Recombinant Protein IL-13Rα2-Fc Is Efficiently
Secreted and Preserves Its Biologic Function After
Transfection of Tumor Cells
B16F10-Nex2 tumor cells were transiently transfectedwith pIL-13R,
and culture supernatants that contained secreted mIL-13Rα2-Fc were
filtered and purified through protein G Sepharose chromatography.
Figure 1. Scheme of DNA construction to produce the mIL-13Rα2-
Fc chimera using overlap PCR. The complete sequences that en-
code the extracellular domain of the IL-13Rα2 receptor (1002 bp)
and the Fc region (654 bp) were joined by a fragment encoding
Gly-Ser-Gly. PCR overlap was done with primers P1 to P4, fol-
lowed by a final PCR with external primers to increase the amount
of the 1665-bp chimera.
Figure 2. Production and analysis of recombinant mIL-13Rα2-Fc
chimera. (A) SDS-PAGE in reducing conditions of recombinant pro-
tein of approximately 85 kDa (arrow). The protein was analyzed after
purification in protein G Sepharose of the supernatant obtained
from transfected B16F10-Nex2 tumor cells after 48 hours of gene
expression. M, protein ladder from Invitrogen; the 80- and 90-kDa
bands are indicated. (B) Immunoblot analysis showing recombinant
protein (chimera IL-13Rα2-Fc) in lane 1 reacting with anti–IL-13Rα2
after staining with DAB reagent. Negative control in lane 2 (super-
natant from transfected cells with empty plasmid). (C) Bioactivity
(binding to IL-13) of the chimera obtained as described in (A) in
chemiluminescent ELISA. The sample (black bar) had 0.92 μg/ml,
according to standardization with commercial chimera (R&D Sys-
tems). The control is the supernatant obtained from transfected
B16F10-Nex2 tumor cells with empty plasmid. *P < .0005, Stu-
dent’s t test.
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The eluate was examined by reduced SDS-PAGE developed with silver
nitrate, showing a recombinant protein of approximately 85 kDa
(Figure 2A). Immunoblot analysis was carried out to confirm its identity
(Figure 2B). The biologic activity (binding to IL-13) was evaluated
by chemiluminescent ELISA test. The sensitivity of this assay was
250 ng/ml, and the concentration of IL-13Rα2-Fc in the sample
was determined from serial dilution of a standard commercial mIL-
13Rα2-hIgG1 (R&D Systems). The sample had 0.92 μg/ml of
mIL-13Rα2-Fc (Figure 2C ). Controls with supernatants obtained
after transfection with the empty vector were used in all experiments.
IL-12 Plasmid
The expression vector encoding IL-12 (pIL-12) was initially tested
in vitro in transfected B16F10-Nex2 tumor cells, followed by ELISA
of the supernatant to evaluate IL-12 production. A high production
of IL-12, ca. 7 ng/ml protein, was obtained. The secreted IL-12 was
biologically active, as judged by its ability to induce NO production
in macrophages from C57Bl/6 mice. Positive controls with lipopoly-
saccharide and IFN-γ were used in all experiments, and negative
controls consisted of macrophages stimulated with supernatant from
cells transfected with the empty vector or untreated. Macrophages
stimulated with 30% of the supernatant obtained after transfection
with pIL-12 showed a production of 57 μM NO, after 72 hours in
culture (data not shown).
Gene Therapy and Association with Drug 7A Effectively
Protected Mice Challenged with B16F10-Nex2 Cells Resulting
in Delayed Tumor Growth and 30% Tumor-Free Animals
C57Bl/6 male mice were injected subcutaneously with 5 × 104
B16F10-Nex2 tumor cells and were vaccinated with pIL-12 alone,
pIL-13R alone, together, and in association with the cyclopalladated
drug 7A. Treatment in vivo with pIL-13R or pIL-12 alone protected
mice significantly prolonging their survival (Figures 3 and 4). DNA
vaccine with pIL-12 prolonged survival to day 39, and the associa-
tion with drug 7A to day 43. DNA vaccine with pIL-13R was also
protective, resulting in increased survival compared to the untreated
control animals until day 41 when administered alone or associated
with drug 7A. The combined therapy with pIL-12 or pIL-13R and
drug 7A significantly delayed tumor growth and was more efficacious
(P < .05) than the therapy with plasmid alone, controlled by vacci-
nation with the empty plasmid. Mice injected with drug 7A alone
were also partially protected and survived until day 42. By adminis-
tering both DNA vaccines associated with drug 7A, the best results
Figure 3. Therapeutic effect of pIL-12 against subcutaneous murine melanoma. (A) Tumor development in animals vaccinated with pIL-
12. (B) Combined treatment with pIL-12 and drug 7A. (C) Increased survival of IL-12 and IL-12 + drug 7A–treated mice. C57Bl/6 mice
were injected with 5 × 104 B16F10-Nex2 tumor cells, and on day 2, the animals were vaccinated with pIL-12 or plasmid with drug 7A.
Drug 7A was administered i.p. three times a week, 10 μM per animal. Control groups were vaccinated with empty plasmid. For each
group, n = 10; Kaplan-Meier test for the control and vaccinated groups with pIL-12 (P = .023) or pIL-12 + drug 7A (P = .009).
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were obtained with protection of 30% of mice that remained tumor-
free until the end of the experiment (Figure 5). In the group vac-
cinated with both plasmids, animals survived until the 47th day.
In all experiments, mice of the control groups died before day 34.
Four control groups were always used, which were vaccinated with
both empty plasmids, with only one empty plasmid (pCMV or
VR1012) and PBS. No significant differences were observed among
these control groups.
Gene Therapy Associated with Drug 7A Induced CD4+ and
CD8+ T Cells as well as F4/80+ Cells Producing Mainly Type I
Proinflammatory Cytokines
The immune response of mice to gene therapy was assessed by
FACS of splenocytes to measure the expression of surface markers
and intracellular interleukins. The results for T lymphocytes are
shown in Figure 6. Untreated, tumor-bearing animals had 2.5%
CD4+ and CD8+ T cells producing IFN-γ compared to 17.6% cells
producing IL-10. Data are representative of three independent ex-
periments with similar results.
Nonvaccinated tumor-bearing mice showed a mixed cytokine pro-
file, with cells producing IFN-γ, IL-6, IL-2, and TNF-α fewer than
cells producing IL-10, IL-13, TGF-β, and IL-4 showing a tendency
toward immunosuppression. Mice challenged with tumor cells and
submitted to biochemotherapy (gene therapy + drug 7A) showed
an increased frequency of cells producing proinflammatory IFN-γ,
IL-6, IL-2, TNF-α, and IL-12 (Table 1). Cells producing IFN-γ
had a relative increase per 100 cells by 15.8-fold. Comparatively,
the CD4+ and CD8+ T cells producing IFN-γ represented 40.9%
compared to 33.6% of IL-10–producing cells (Figure 6). Other cyto-
kines were also produced such as TNF-α (42.1%), IL-6 (41.0%),
and IL-2 (39.5%) with a balance toward a proinflammatory type I re-
sponse. As expected, treatment also increased the number of F4/80+
cells producing IL-12 (25.1%), more than eightfold compared to
cells from untreated mice (3.0%) and sevenfold more IL-6 as well.
Figure 4. Therapeutic effect of pIL-13R against subcutaneous murine melanoma. (A) Tumor development in animals vaccinated with pIL-
13R. (B) Combined treatment with pIL-13R and drug 7A. (C) Increased survival of pIL-13R and pIL-13R plus drug 7A–treated mice. C57Bl/
6 mice were injected with 5 × 104 B16F10-Nex2 tumor cells, and on days 5, 10, 15, 20, 25 and 30, the animals were vaccinated with pIL-
13R (plasmid VR1012 containing the insert IL-13Rα2-Fc; (A). The same protocol was used in association with drug 7A (B). Drug 7A was
administered i.p. three times a week, 10 μM per animal. Control groups were vaccinated with empty plasmid. For each group, n = 10.
Kaplan-Meier test for the control and the vaccinated groups with pIL-13R (P = .0298) or with pIL-13R + drug 7A (P = .0005).
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Cells producing IL-4, TGF-β, and IL-13 were also represented with
12.1%, 29.5%, and 31.9%, respectively. Therefore, the combined
gene therapy and drug treatment, although showing a marked proin-
flammatory immune response, also produced type II cytokines. The
inflammation induced by DNA vaccines is then controlled by immu-
noregulatory cytokines. It seems that IFN-γ production is the most
important cytokine for a protective effect against melanoma cells [38]
and that the IFN-γ/IL-10 ratio must be >1 as in the vaccinated mice.
NK1.1+ T Cells Increase IFN-γ Production in Mice Given the
Combined Therapy
Among splenocytes, populations of NK1.1+ T cells (CD3+NK1.1+,
CD4+NK1.1+, and CD8+NK1.1+ cells) were also evaluated for their
ability to produce IFN-γ, IL-10, and IL-13. NK1.1+ T cells include
classic NKT cells (type I cells), nonclassic NKT cells (type II cells),
and NKT-like cells. CD3+NK1.1+ cells included CD4/CD8 double-
negative cells (CD4−CD8−NK1.1+). Cells were labeled simultaneously
with three fluorescent conjugates, and the results are summarized
in Figure 7. The combined therapy used in the present work in-
duced IFN-γ production and down-regulated IL-10 and IL-13. Ac-
cordingly, NKT cells from vaccinated mice produced much more
IFN-γ than those from untreated tumor-bearing mice (Figure 7).
Seemingly, a polarized immune response was induced. Type I NKT
cells predominated in mice given biochemotherapy and were responsi-
ble for IFN-γ production, whereas untreated mice had more type II
NKT cells that were responsible for IL-13 and IL-10 production.
In these subpopulations, CD4+NK1.1+ cells were the main source of
IL-13 in tumor-bearing mice, and after therapy, this production was
abolished (Figure 7B). Cells with bothmarkers (CD4+NK1.1+) also pro-
duced more IFN-γ than other subpopulations in vaccinated mice.
Discussion
In the present work, we report on the protective effect in vivo of
gene therapy with plasmids expressing IL-12 and IL-13Rα2-Fc in a
Figure 5. Therapeutic effects of gene therapy with and without cyclopalladated drug 7A against subcutaneous murine melanoma. (A)
Tumor development in animals vaccinated with pIL-12 plus pIL-13R or (B) both plasmids in association with drug 7A. (C) Survival curves
with 30% tumor-free animals in the biochemotherapy protocol. C57Bl/6 mice were injected with 5 × 104 B16F10-Nex2 tumor cells; on
day 2, the animals were vaccinated with pIL-12; and on days 5, 10, 15, 20, 25, and 30 with pIL-13R. Drug 7A was administered i.p., three
times a week, 10 μM per animal. Control groups were vaccinated with the empty plasmid. For each group, n = 10. Kaplan-Meier test for
the control group (empty vectors) and the vaccinated group with both plasmids (P= .0005) or the vaccinated group with both plasmids +
drug 7A (P = .0001).
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murine melanoma model. A protocol of biochemotherapy was then
introduced combining immunization with both plasmids and che-
motherapy with a cyclopalladated drug (7A). Biochemotherapy is a
term generally used for combined treatment of biologic agents such
as cytokines, antigen-pulsed DCs or lymphocytes, and chemothera-
peutic drugs.
Clinical trials focusing on malignant melanoma have tested IL-2,
IFN-α, and lymphokine-activated killer cells stimulated with IL-2
[39,40]. These agents showed reproducible antitumor effects but
with low efficacy. Perhaps, administration of inflammatory cytokines
alone (and other immune activators) is not sufficient to cause tumor
regression in the presence of suppressor elements that regulate the
immune response leading to a poor in vivo CTL activity. The admin-
istration of proinflammatory cytokines and blockade of immuno-
suppressive components could be essential to the control of tumor
development thus increasing the efficacy of antitumor vaccines
[41]. Here, we used gene therapy with genes encoding IL-12 and
IL-13-receptor associated with chemotherapy. This combined strat-
egy induced a protective immune response and was successful in
prolonging animal survival in the B16F10-Nex2 melanoma model.
Cytokine IL-12 included in the gene therapy protocol mediates
effector mechanisms of both innate and adaptive immunity to render
antitumor resistance. IFN-γ and many other secondary proinflam-
matory cytokines induced by IL-12 have a direct toxic effect on
the tumor cells and may act as antiangiogenic elements [42,43].
Mechanisms responsible for IL-12–mediated tumor rejection in sev-
eral experimental models have been investigated showing that IL-12
uses a variety of effector pathways involving NK, NKT, CD4+, and
CD8+ T cells. IL-12 pretreatment enhanced immunotherapy with
low doses of IFN-α, and this effect was dependent on endogenous
IFN-γ production [44]. Gene gun therapy with plasmid encoding
IL-12 resulted in complete tumor regression or suppression of tumor
growth in six tumor models, including murine B16 melanoma [35].
The involvement of CD8+ T cells was confirmed after in vivo deple-
tion of these cells. Moreover, IL-12 therapy led to the generation of
tumor-specific immunologic memory in at least three tumor models.
These data are in agreement with the findings of Brunda et al. [45]
who reported that tumor regression caused by IL-12 is mediated by
CD8+ T cells, whereas NK cells seemed less important for antitu-
mor effects. Another study showed that plasmid delivery of IL-12
by in vivo electroporation was an efficacious strategy against B16F10
murine melanoma. Intratumor but not intramuscular treatment re-
sulted in the cure of 47% of tumor-bearing mice, and tumor rejection
was mediated by IFN-γ, tumor-infiltrating lymphocytes, and anti-
angiogenic effects [46]. Natural killer T cells have also been implicated
in IL-12–mediated tumor rejection [12,47]. After administration of
IL-12, NKT cells were a primary functional target in vivo, and they
were important for tumor rejection in at least three tumor models:
B16 melanoma, Lewis lung carcinoma, and FBL3 erythroleukemia
[12]. Park et al. [48] revealed other mechanisms leading to tumor
rejection under IL-12 treatment, by which NK cells mediated the re-
jection of liver metastases, and lymphoid DCs were possibly responsi-
ble for rejection of skin tumors. Therapeutic doses of IL-12 were as
effective in normal mice as in NKT-deficient mice (CD1-deficient),
using one of the tumor types and the same IL-12 treatment regimen
Figure 6. Analysis of T lymphocyte population using FACS from
tumor-bearing animals untreated (control group) and vaccinatedwith
both plasmids in association with drug 7A. Cells were labeled with
PE-conjugated anti-CD4 mAb or PE-conjugated anti-CD8 mAb. After
permeabilization, intracellular detection of the cytokines was carried
out with anti–cytokine biotinylated antibody and labeling with FITC-
conjugated streptavidin. Data are shown as percentages of double-
positive cells (CD4/CD8 and IFN-γ/IL-10) and are representative of
three independent experiments with similar results. Table 1. Increase with Biochemotherapy for Cytokine Expressing Cells Defining a Proinflamma-
tory Response with Low Type II Interleukins.
Cytokine Expression Population Fold-Increase Relative to
100 Cells (95% Confidence Intervals)*
1. CD4+ plus CD8+ cells
IFN-γ† 16.67 (2.938-30.408)
IL-2 3.0 (1.468-4.576)
IL-6† 18.85 (2.418-27.297)
TNF-α 2.49 (1.485-3.498)
IL-4‡ 1.21 (0.938-1.473)
IL-13 3.0 (1.866-4.265)
TGF-β 3.56 (1.086-6.049)
IL-10 1.64 (1.007-2.276)
2. F4/80+ cells
IL-12 5.35 (2.898-7.795)
IL-6 6.29 (3.092-9.502)
TNF-α 2.96 (1.764-4.172)
*Cytokine rates from cells of 11 pairs of treated and control (untreated) animals.
†Significant differences between IFN-γ and IL-4 and IL-10 (P < .001) or IL-6 and IL-4 and IL-10
(P < .001 and P < .01, respectively).
‡Only CD4+ cells.
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as Cui et al. [12]. Although their results failed to confirm an essential
role of NKT cells in B16 melanoma, Park et al. [48] agreed that IL-12
can stimulate diverse mechanisms of resistance to tumors, depending
on tumor cell type, tumor microenvironment, and mouse strain. In
our B16F10-Nex2 system, it is clear that CD1d-dependent NKT cells
are critical for antitumor response in untreated tumor-bearing mice
(Dias et al., unpublished data). Type I NKT cells predominated in vac-
cinated mice and were responsible for IFN-γ production which is the
key factor in antimelanoma immune response. Some other studies
confirmed the critical role of NKT cells in antitumor response, in
which NKT cells promote potent tumor rejection in response to
exogenous factors such as IL-12 [49] and α-GalCer [11,50,51] as
well as in the absence of exogenous stimuli [8,52]. Smyth et al.
[49] demonstrated that, at high dose, IL-12 induced tumor immu-
nity mediated preferentially by NK cells in a perforin-dependent
mechanism. In B16F10 melanoma and RM-1 prostate carcinoma
tumor models, a lower IL-12 dose or delayed administration of
IL-12 revealed the role of NKT cells in tumor protection. Both
NK and NKT cells thus seem to contribute to natural and IL-12–
induced immunity against tumors, and the relative role of each popu-
lation is tumor- and therapy-dependent.
Not all NK1.1+ T cells are classic NKT cells [53]. NK1.1+ T cells
include type I and type II NKT cells (CD1d-dependent) and other
NKT-like cells (CD1d-independent). When type I and type II NKT
cells were stimulated simultaneously, type II NKT cells seemed to
suppress the activation in vitro and the protective effect in vivo of
type I NKT cells. Furthermore, when type I cells were absent, the
suppressive effect of type II cells increased, suggesting that type I cells
can control the suppressive effects of type II NKT cells in a new im-
munoregulatory axis [6,54].
Our strategy for antitumor immune protection through gene ther-
apy aimed at stimulating IFN-γ production by type I NKT cells
among other cells stimulated by IL-12 while suppressing the immu-
noregulatory properties of type II NKT cells. In fact, type II NKT
cells were responsible for IL-13–mediated inhibition of tumor im-
munosurveillance [14]. Interleukin 13 has emerged as an important
mediator of TH2 immune response with immunoregulatory activities
in many experimental models such as allergic asthma [55,56], schis-
tosomiasis [57,58], leishmaniasis [59], nematode parasitism [60], fi-
brosis [26], and cancer [3–5,7,61]. IL-13 produced by CD4+ T cells
inhibited CD8+ CTL [3] by inducing the production of TGF-β by
CD11b+Gr-1+ myeloid–derived cells [4]. Another mechanism pro-
posed for IL-13–mediated immunosuppression is macrophage polar-
ization toward the M2 phenotype, inhibiting the generation of
tumoricidal M1 macrophages [5]. We, therefore, engineered a con-
struct containing the cDNA encoding IL-13 receptor chain-2 fused
to the Fc region of mIgG2a and obtained the IL-13Rα2-Fc chimera
DNA vaccine. As also described by Zheng et al. [37], we observed
that IL-13Rα2 is regulated by its own ligand, IL-13. Macrophages
stimulated with IL-13 expressed the IL-13α2 receptor unlike the un-
stimulated macrophages. Recent studies showed that therapy with
soluble IL-13Rα2-Fc protein effectively stimulated antitumor immu-
nity, enhanced vaccine efficacy, and prevented some chronic diseases
[3,13,57,61]. Therefore, IL-13Rα2 may act as a “decoy receptor,”
suppressing the action of the IL-13, thus helping to maintain tumor
immunosurveillance [3]. Presently, we show that treatment of
C57Bl/6 mice with plasmid containing IL-13Rα2-Fc vaccine and/
or plasmid encoding IL-12 significantly prolonged survival of mice
challenged with tumor cells and that the combined gene therapy
and chemotherapy conferred a significant level of protection against
B16F10-Nex2. Such therapy led to a high production of proinflam-
matory cytokines by CD4+ and CD8+ cells, particularly IFN-γ. Anti-
inflammatory cytokines were produced in greater amounts in cells
from unvaccinated tumor-bearing mice. Analysis of the NKT subsets
showed a type I/type II balance, as in an immunoregulatory axis [6]
with cytokines being produced depending on the stimulus. It has
been shown that NKT cells can produce IFN-γ, IL-4, IL-10, and
IL-13 [62–64]. Presently, we show that CD4+NK1.1+ cells from vac-
cinated mice produced threefold more IFN-γ than cells from unvac-
cinated mice, probably by a mechanism mediated by IL-12 DNA
vaccine. In addition, CD4+NK1.1+ cells from tumor-bearing mice
without any vaccine treatment or exogenous stimulus produced pre-
dominantly IL-13 but did not produce detectable IFN-γ, and this
IL-13 production was abolished after combined therapy. After ther-
apy with IL-12 and IL-13 receptor DNA vaccines associated with
Figure 7. Cytokine expression in NK1.1+ T cells by using FACS.
The splenocytes were obtained from tumor-bearing animals vac-
cinated with both plasmids in association with drug 7A (black
bars) or injected with PBS (white bars). (A) Cells were labeled with
FITC-conjugated anti-NK1.1 monoclonal antibody (mAb) and PE-
conjugated anti–CD3 mAb or (B) PE-conjugated anti-CD4 mAb or
(C) PE-conjugated anti-CD8 mAb. Intracellular detection of cyto-
kines in permeabilized cells was carried out with anti–cytokine bio-
tinylated antibody and labeled with APC-conjugated streptavidin.
Data are representative of three independent experiments with
similar results and show the percentage of the positive labeled
cells for each cytokine within a defined subpopulation.
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drug 7A, cells produced IFN-γ instead of IL-10 and IL-13. Recently,
the existence of functionally distinct NKT cell subsets has been rec-
ognized [65]. The authors demonstrated that murine type I NKT
cells that responded to α-GalCer–mediated antitumor activity are
found only in the liver-derived CD4−CD8− subset but not in the
CD4+ subset. Spleen- and thymus-derived NKT cells did not confer
similar protective responses. CD4+ NKT cells could be the exclusive
producers of interleukins IL-4 and IL-13 on primary stimulation,
whereas double-negative NKT cells had a strict TH1 profile [63]. Ac-
cording to our results, CD4+ NKT cells can produce both TH1 and
TH2 cytokines as also found by Gumperz et al. [66]. In conclusion,
we observed a significant delay in tumor evolution and prolonged
survival using a protocol of one dose of pIL-12 followed by six doses
of pIL-13R and continuous treatment with cyclopalladated drug 7A,
obtaining 30% of tumor-free mice. To elucidate the mechanisms that
mediated the antitumor effects, we assessed the T cells producing
cytokines in the tumor-bearing mice that had been vaccinated with
the complete protocol. In vivo induction of proinflammatory cyto-
kines was detected in mice given gene therapy plus chemotherapy, sug-
gesting that it was sufficient to stimulate a strong immune response
mediated by IFN-γ production. Likely IFN-γ increase was IL-12–
mediated and IL-13 decreased on administration of IL-13Rα2-Fc
vaccine, whereas drug 7A directly killed B16F10-Nex2 tumor cells.
These results can also be explained by immunoregulatory NKT cells
of different subsets producing functionally distinct cytokines.
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